Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MERTK | Q12866 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | KAT2B | Q92831 | 4/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19172520 | 0.86 | LMNA (0.51) | MAPTKDM4EMERTKGAALMNA | |
| SCHEMBL7018840 | 0.83 | MERTK (0.42) | MAPTMERTKTXNRD1KMT2A | |
| SCHEMBL25289487 | 0.81 | MERTK (0.44) | MAPTMERTKTXNRD1 | |
| SCHEMBL4669978 | 0.80 | MAPT (0.46) | MAPTKDM4EGAAGLAKAT2B | |
| SCHEMBL16931464 | 0.76 | LMNA (0.49) | MAPTKDM4ELMNAKMT2A | |
| SCHEMBL25637893 | 0.75 | BRD4 (0.47) | MAPTMERTKTXNRD1LMNAKMT2A | |
| SCHEMBL9794390 | 0.75 | TXNRD1 (0.50) | MAPTTXNRD1 | |
| SCHEMBL23552720 | 0.75 | SYK (0.41) | SYKKDM4E | |
| SCHEMBL19172436 | 0.74 | LMNA (0.47) | MAPTKDM4EGAATXNRD1LMNA | |
| SCHEMBL25637792 | 0.73 | CYP1A2 (0.49) | MAPTKDM4EGAAGLACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490093-A4 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ISCHEMIA | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2007-04-11 | — | — | EP | disclosed |
| EP-1490093-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ISCHEMIA | CHIRON CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| EP-1087963-B1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORP (US) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003074072-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ISCHEMIA | CHIRON CORPORATION (US) | 2003-09-12 | — | — | WO | disclosed |
| EP-1317433-A2 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2003-06-11 | — | — | EP | disclosed |
| WO-2002020495-A2 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2002-03-14 | — | — | WO | disclosed |
| EP-1087963-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | Chiron Corporation (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065897-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 1999-12-23 | — | — | WO | disclosed |